Pulmonary vascular disease & thromboembolismSecondary analysis
Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients
- Secondary analysis of the CLEAR Outcomes randomised trial
- double-blind
- placebo-controlled
- 1250 centres in 32 countries
Authors' conclusion
Treatment with bempedoic acid among participants with statin intolerance at high risk for or with established cardiovascular disease was associated with a reduced risk of VTE.
Study context
- Population
- Statin-intolerant adults aged 18 to 85 years at high risk for or with established atherosclerotic CVDmedian follow-up 40.6 months
- Participants
- 13,970 adults
- Comparison
- Bempedoic acid vs placebo
- Bempedoic acidn = 6,992
- Placebon = 6,978reference
- Primary endpoint
- Time to first venous thromboembolism (VTE) (DVT or PE)
Primary result
VTE
Hazard ratio
0.58
95% CI 0.39–0.86
P = 0.006
Events by treatment group
Bempedoic acid
39
events
Placebo
67
events
Bempedoic acid vs Placebo
HR 0.58 (95% CI 0.39–0.86); P = 0.006
As reported in the abstract
Further findings
DVT
- Consistent with primary result: HR 0.56 (95% CI 0.31-0.996)
- P = 0.045
PE
- Consistent with primary result: HR 0.61 (95% CI 0.37-0.996)
- P = 0.046
Original publication
Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients. JAMA Cardiol. Published 1 July 2026. doi:10.1001/jamacardio.2026.1208
Summarised from the published abstract; every number is checked against it